SCHEMBL6419677

SCHEMBL6419677

CC(C)(C)OC(=O)NNc1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.49
MEN1 O00255 2/20 0.49
RAB9A P51151 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 5/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
CDKN1A P38936 1/20 0.41
ABCG2 Q9UNQ0 2/20 0.40
POLB P06746 2/20 0.39
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
BRD4 O60885 3/20 0.38
SYK P43405 1/20 0.37
RECQL P46063 1/20 0.37
CCR2 P41597 1/20 0.36
CCR5 P51681 1/20 0.36
ABCB1 P08183 1/20 0.36
TOP2A P11388 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419799 0.88 SMN1; SMN2 (0.48) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6416313 0.87 MAPT (0.47) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6416039 0.85 MEN1 (0.44) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6416982 0.83 MAPT (0.45) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6414619 0.83 MEN1 (0.46) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6414113 0.81 EGFR (0.49) MEN1KMT2ATP53MAPTSMN1; SMN2
SCHEMBL6414172 0.77 GAA (0.40) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6414257 0.76 GAA (0.39) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL6439454 0.76 GAA (0.45) GAAMEN1RAB9AKMT2ANPC1
SCHEMBL3051333 0.76 MAPT (0.54) GAAMEN1RAB9AKMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 GAA 3186/4885MEN1 4392/4885RAB9A 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.